Segment Reporting Disclosure [Text Block] |
In accordance with FASB ASC 280, “Segment Reporting,” the Company discloses financial and descriptive information about its reportable segments. The Company operates in two segments, iBio, Inc. and iBio CDMO. Commencing July 1, 2016, management determined that the activity of iBio CDMO should be segregated as a separate segment. In addition, management determined that the activity of iBio Brazil was no longer material and will be included in the activity of iBio, Inc. As such, the segment information for the year ended June 30, 2016 was conformed to the current presentation. These segments are components of the Company about which separate financial information is available and regularly evaluated by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The accounting policies of the segments are the same as those described in the Summary of Significant Accounting Policies. Year Ended June 30, 2017 (in thousands) | | iBio, Inc. | | iBio CDMO | | Eliminations | | Total | | | | | | | | | | | | | | | | Revenues - external customers | | $ | 271 | | $ | 123 | | $ | - | | $ | 394 | | Revenues - intersegment | | | 972 | | | 1,280 | | | (2,252) | | | - | | Research and development | | | 3,657 | | | 1,763 | | | (1,303) | | | 4,117 | | General and administrative | | | 5,245 | | | 6,255 | | | (949) | | | 10,551 | | Operating loss | | | (7,659) | | | (6,615) | | | - | | | (14,274) | | Interest expense | | | (1) | | | (1,928) | | | - | | | (1,929) | | Interest and other income | | | 43 | | | 21 | | | - | | | 64 | | Consolidated net loss | | | (7,617) | | | (8,522) | | | - | | | (16,139) | | Total assets | | | 19,049 | | | 29,738 | | | (12,777) | | | 36,010 | | Fixed assets, net | | | 8 | | | 25,581 | | | - | | | 25,589 | | Intangible assets, net | | | 1,823 | | | - | | | - | | | 1,823 | | Depreciation expense | | | 3 | | | 1,323 | | | - | | | 1,326 | | Amortization of intangible assets | | | 350 | | | - | | | - | | | 350 | | Year Ended June 30, 2016 (in thousands) | | iBio, Inc. | | iBio CDMO * | | Eliminations | | Total | | | | | | | | | | | | | | | | Revenues - external customers | | $ | 893 | | $ | 55 | | $ | - | | $ | 948 | | Revenues - intersegment | | | 158 | | | 324 | | | (482) | | | - | | Research and development | | | 2,984 | | | 501 | | | (329) | | | 3,156 | | General and administrative | | | 5,560 | | | 2,278 | | | (153) | | | 7,685 | | Operating loss | | | (7,493) | | | (2,400) | | | - | | | (9,893) | | Interest expense | | | - | | | (807) | | | - | | | (807) | | Interest and other income | | | 33 | | | 10 | | | - | | | 43 | | Consolidated net loss | | | (7,460) | | | (3,197) | | | - | | | (10,657) | | Total assets | | | 13,393 | | | 38,282 | | | (75) | | | 51,600 | | Fixed assets, net | | | 8 | | | 25,566 | | | - | | | 25,574 | | Intangible assets, net | | | 2,092 | | | - | | | - | | | 2,092 | | Depreciation expense | | | 4 | | | 573 | | | - | | | 577 | | Amortization of intangible assets | | | 363 | | | - | | | - | | | 363 | | * | iBio CDMO commenced operations in December 2015. |
|